Abbott blood screening
This article was originally published in The Gray Sheet
Abbott announces biologics license approval Jan. 18 for a fully automated blood screening test for antibodies to human T-lymphotropic virus Types I and II on the firm's Prism system. The HTLV-I and II retroviruses are associated with leukemia and neurological disorders, among other diseases, and are screened for in all U.S. blood donations. Abbott says the new test offers an alternative to its HTLV-I/II assay approved in 1997 that runs on the semi-automated Commander system. Prism, which launched in the U.S. in 2005, also runs four tests for hepatitis
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.